TABLE 2.
TCGA baseline clinical characteristics of gene expression subtypes and single-factor analysis.
| Gene_expression_subtypes | ||||||
|---|---|---|---|---|---|---|
| Characteristics | Total | Differentiated | Immunoreactive | Mesenchymal | Proliferative | p value |
| Age | 59.12 ± 10.977 | 55.14 ± 9.38 | 58.69 ± 10.99 | 61.23 ± 11.30 | 61.06 ± 11.16 | 0.002* |
| OS time | 949 (442–1579) | 1032 (449.5–1488) | 1059 (448–1754.5) | 787 (481.5–1366.5) | 907.5 (369.25–1685.75) | 0.574 |
| OS | ||||||
| Live | 120 | 22 | 44 | 23 | 31 | 0.035* |
| Dead | 183 | 47 | 37 | 46 | 53 | |
| no available | 5 | 1 | 3 | 0 | 1 | |
| Stage | ||||||
| I | 1 | 0 | 0 | 1 | 0 | 0.092 |
| II | 21 | 5 | 8 | 1 | 7 | |
| III | 242 | 48 | 65 | 60 | 69 | |
| IV | 38 | 16 | 8 | 6 | 8 | |
| no available | 6 | 1 | 3 | 1 | 1 | |
| Grade | ||||||
| G1 | 1 | 0 | 0 | 1 | 0 | 0.861 |
| G2 | 35 | 7 | 7 | 11 | 10 | |
| G3 | 261 | 61 | 73 | 56 | 21 | |
| G4 | 1 | 0 | 0 | 0 | 1 | |
| GX | 4 | 1 | 1 | 1 | 1 | |
| no available | 6 | 1 | 3 | 0 | 2 | |
| New event type | ||||||
| locoregional Disease | 4 | 3 | 1 | 0 | 0 | 0.141 |
| metastatic | 1 | 0 | 0 | 1 | 0 | |
| progression of Disease | 12 | 2 | 2 | 1 | 7 | |
| recurrence | 151 | 33 | 39 | 37 | 42 | |
| no available | 140 | 32 | 42 | 30 | 36 | |
| Cancer status | ||||||
| tumor free | 69 | 16 | 20 | 13 | 20 | 0.335 |
| with tumor | 197 | 49 | 47 | 47 | 54 | |
| no available | 42 | 5 | 17 | 9 | 11 | |
| Anatomic site | ||||||
| Bilateral | 209 | 52 | 51 | 48 | 58 | 0.577 |
| Left | 36 | 6 | 13 | 7 | 10 | |
| Right | 42 | 11 | 12 | 8 | 11 | |
| no available | 21 | 1 | 8 | 6 | 6 | |
| Initial pathologic diagnosis method | ||||||
| cytology (e.g., peritoneal or pleural fluid) | 27 | 5 | 9 | 10 | 3 | 0.402 |
| excisional Biopsy | 5 | 2 | 1 | 2 | 0 | |
| fine needle aspiration biopsy | 3 | 0 | 1 | 1 | 1 | |
| tumor resection | 265 | 61 | 70 | 56 | 78 | |
| other method | 8 | 2 | 3 | 0 | 3 | |
*Statistically significant (p-value < 0.05).
The four gene expression subtypes of OV are differentiated, immunoreactive, mesenchymal, and proliferative types in TCGA.